武汉大学王茜博士与刘立鸿博士联合课题组2025年招聘科研助理与博士后

发布时间：2025-04-28

截止日期：2025-10-24

学历要求：本科及以上

所属省份：湖北

工作地点：武汉

王茜博士为国家级海外高层次人才青年项目获得者，将于2025年5月全职加入武汉大学，任生命科学学院教授、高致病性病毒与生物安全全国重点实验室教授、泰康生命医学中心教授，博士生导师。王茜博士于2018年获得清华大学博士学位，随后在哈佛大学 Joseph G. Sodroski 教授实验室开展博士后研究，并在哥伦比亚大学何大一教授（Dr. David Ho）实验室担任高级副研究员（Associate Research Scientist）。自2024年5月至2025年4月，任美国哥伦比亚大学助理教授（Assistant Professor），并曾荣获2023年度《麻省理工科技评论》（MIT Technology Review）“35岁以下科技创新35人（Innovators Under 35）中国区入选者”。

联合实验室的另一位导师为刘立鸿博士，国家级海外高层次人才青年项目获得者。刘立鸿博士已于2024年5月全职加入武汉大学，现任武汉大学生命科学学院教授、高致病性病毒与生物安全全国重点实验室教授、泰康生命医学中心教授。刘立鸿博士于2015年在中国科学院上海巴斯德研究所获得博士学位，随后在美国洛克菲勒大学艾伦·戴蒙德艾滋病研究中心何大一教授（Dr. David Ho）课题组开展博士后研究。2021年至2024年，任美国哥伦比亚大学助理教授（Assistant Professor）。刘立鸿博士科研成果突出，2025年荣获首届Wiley新锐科学家奖。

王茜博士与刘立鸿博士在冠状病毒（包括新冠）和艾滋病研究领域取得了一系列突出成果，分别以第一作者或通讯作者身份在 Nature（6 篇）、Cell、New England Journal of Medicine（NEJM，2 篇）、The Lancet、Immunity、Science Translational Medicine、Cell Host & Microbe（2 篇）、Cell Reports（3 篇）、Cell Reports Medicine（2 篇）、The Lancet Infectious Diseases（4 篇）、Journal of Virology（5 篇）等国际著名期刊发表研究论文。两位学者的研究成果在学术界产生广泛影响，谷歌学术总引用超过 16,500 次。

联合实验室将聚焦重大传染性疾病对公共卫生安全的影响，带领团队开展病毒进化、感染机制及人体体液免疫应答等方向的研究，致力于揭示病毒长期演化与公共健康风险之间的内在联系。因课题组发展需要，现诚挚欢迎对相关研究方向感兴趣的有志之士加入我们的联合团队，共同推动科学发现与技术转化。

一、招聘流程及要求

现招聘科研助理和博士后！诚挚欢迎感兴趣的有志之士加入联合团队，有意者请将以下材料发送至：llh3411@whu.edu.cn 。邮件标题请注明“应聘岗位名称+姓名”。初审通过后，将通知安排面试，择优录取。应聘材料将予以保密。

1.个人简历，包括学习工作经历、主要研究方向、代表性论文论著清单、获奖情况。

2.学历学位证书、身份证扫描件。

3. Cover letter: 简要介绍既往工作、研究兴趣和职业规划。

4.申请人认为其他有借鉴意义的材料。

5.两封推荐信，包括硕士或博士导师推荐信一封。推荐信应由推荐人邮箱直接发出。

01科研助理：

1.生物学相关专业本科或硕士，具有良好的英文读写能力；

2.团队管理能力；

3.根据武汉大学相关规定以及个人工作能力，提供具有竞争力的薪酬待遇，具体薪资面谈。

02博士后：

1.已获得或即将获得生命科学相关专业博士学位，有病毒学、生物信息学、免疫学、疫苗学、结构生物学等相关研究背景者优先；

2.具有良好的中英文写作能力，以第一作者身份在国际权威期刊发表过原创性研究论文；

3.身心健康，为人诚信，乐于团队协作，具有独立开展科研工作的能力。

4.具体待遇一人一议，请参考武汉大学博士后管理规定：

https://mp.weixin.qq.com/s/OcpHJtxaGg_wWazeXxlV7Q

该招聘长期有效，招满为止。

代表性发表的论文：（* 第一作者，# 通讯作者）

1.Wang Q, Guo Y, Mellis IA, Wu M, Mohri H, Gherasim C, Valdez R, Purpura LJ, Yin MT, Gordon A, Ho DD. Antibody evasiveness of SARS-CoV-2 subvariants KP.3.1.1 and XEC. Cell Reports. 2025 Apr 8;44(4):115543. doi: 10.1016/j.celrep.2025.115543.

2.Wang Q, Mellis IA, Wu M, Bowen A, Gherasim C, Valdez R, Shah JG, Purpura LJ, Yin MT, Gordon A, Guo Y, Ho DD. KP.2-based monovalent mRNA vaccines robustly boost antibody responses to SARS-CoV-2. The Lancet Infectious Diseases 2025 Feb 4:S1473-3099(25)00058-1.

3.Wang Q, Guo Y, Ho J, Ho DD. Activity of Research-Grade Pemivibart against Recent SARS-CoV-2 JN.1 Sublineages. New England Journal of Medicine 2024 Nov 14;391(19):1863-1864.

4.Wang Q, Mellis IA, Ho J, Bowen A, Kowalski-Dobson T, Valdez R, Katsamba PS, Wu M, Lee C, Shapiro L, Gordon A, Guo Y, Ho DD, Liu L#. Recurrent SARS-CoV-2 spike mutations confer growth advantages to select JN.1 sublineages. Emerging Microbes & Infections 2024 Sep 11:2402880.

5.Wang Q, Mellis IA, Guo Y, Gherasim C, Valdez R, Gordon A, Ho DD, Liu L#. Robust SARS-CoV-2-neutralizing antibodies sustained through 6 months post XBB.1.5 mRNA vaccine booster. Cell Reports Medicine 2024 Aug 23:101701.

6.Wang Q, Guo Y, Bowen A, Mellis IA, Valdez R, Gherasim C, Gordon A, Liu L#, Ho DD. XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against emerging SARS-CoV-2 variants. Cell Host & Microbe 2024 Mar 13;32(3):315-321.e3.

7.Wang Q, Guo Y, Schwanz LT, Mellis IA, Sun Y, Qu Y, Urtecho G, Valdez R, Stoneman E, Gordon A, Wang HH, Ho DD, Liu L#. SARS-CoV-2 omicron BA.2.87.1 exhibits higher susceptibility to serum neutralization than EG.5.1 and JN.1. Emerging Microbes & Infections 2024 Dec;13(1):2359004.

8.Wang Q, Zhang S, Nguyen HT, Sodroski JG. Inhibition of human immunodeficiency virus (HIV-1) infectivity by expression of poorly or broadly neutralizing antibodies against Env in virus-producing cells. Journal of Virology 2024 Feb 20;98(2):e0159423.

9.Liu L*,#, Casner RA*, Guo Y*, Wang Q*, Iketani S, Chan JFW, Yu J, Dadonaite B, Nair MS, Mohri H, Reddem ER, Yuan S, Poon VK, Chan CC, Yuen KY, Sheng Z, Huang Y, Bloom JD, Shapiro L, Ho DD. Antibodies targeting a quaternary site on SARS-CoV-2 spike glycoprotein prevent viral receptor engagement by conformational locking. Immunity. 2023 Oct 10;56(10):2442-2455.e8.

10.Wang Q, Guo Y, Liu L, Schwanz LT, Li Z, Nair MS, Ho J, Zhang RM, Iketani S, Yu J, Huang Y, Qu Y, Valdez R, Lauring AS, Huang Y, Gordon A, Wang HH, Liu L#, Ho DD. Antigenicity and receptor affinity of SARS-CoV-2 BA.2.86 spike. Nature 2023 Dec;624(7992):639-644.

11.Wang Q, Guo Y, Tam AR, Valdez R, Gordon A, Liu L#, Ho DD. Deep immunological imprinting due to the ancestral spike in the current bivalent COVID-19 vaccine. Cell Reports Medicine 2023 Nov 21;4(11):101258.

12.Wang Q, Bowen A, Ho J, Zhang RM, Valdez R, Stoneman E, Gordon A, Liu L#, Ho DD. SARS-CoV-2 neutralising antibodies after a second BA.5 bivalent booster. Lancet 2023 Nov 18;402(10415):1827-1828.

13.Wang Q, Guo Y, Zhang RM, Ho J, Mohri H, Valdez R, Manthei DM, Gordon A, Liu L#, Ho DD. Antibody neutralisation of emerging SARS-CoV-2 subvariants: EG.5.1 and XBC.1.6. The Lancet Infectious Diseases 2023 Oct;23(10):e397-e398.

14.Wang Q, Li Z, Guo Y, Mellis IA, Iketani S, Liu M, Yu J, Valdez R, Lauring AS, Sheng Z, Gordon A, Liu L#, Ho DD. Evolving antibody evasion and receptor affinity of the Omicron BA.2.75 sublineage of SARS-CoV-2. iScience 2023 Oct 18;26(11):108254.

15.Zhang Z*, Wang Q*, Nguyen HT, Smith AB, Sodroski JG. Alterations in gp120 Glycans or the gp41 Fusion Peptide-Proximal Region Modulate the Stability of the Human Immunodeficiency Virus (HIV-1) Envelope Glycoprotein Pretriggered Conformation. Journal of Virology 2023 Sep 28;97(9):e0059223.

16.Wang Q, Bowen A, Tam AR, Valdez R, Stoneman E, Mellis IA, Gordon A, Liu L#, Ho DD. SARS-CoV-2 Neutralizing Antibodies After Bivalent vs. Monovalent Booster. The Lancet Infectious Diseases 2023 May;23(5):527-528.

17.Wang Q, Yeh AY, Guo Y, Mohri H, Yu J, Ho DD, Liu L#. Impaired potency of neutralizing antibodies against cell-cell fusion mediated by SARS-CoV-2. Emerging Microbes & Infections 2023 May 3:2210237.

18.Wang Q, Bowen A, Valdez R, Gherasim C, Gordon A, Liu L#, Ho DD. Antibody Response to Omicron BA.4-BA.5 Bivalent Booster. New England Journal of Medicine 2023 Feb 9;388(6):567-569.

19.Wang Q, Iketani S, Li Z, Liu L, Guo Y, Huang Y, Bowen AD, Liu M, Wang M, Yu J, Valdez R, Lauring AS, Sheng Z, Wang HH, Gordon A, Liu L#, Ho DD. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell 2023 Jan 19;186(2):279-286.e8.

20.Liu L, Iketani S, Guo Y, Reddem ER, Casner RG, Nair MS, Yu J, Chan JF, Wang M, Cerutti G, Li Z, Morano NC, Castagna CD, Corredor L, Chu H, Yuan S, Poon VK, Chan CC, Chen Z, Luo Y, Cunningham M, Chavez A, Yin MT, Perlin DS, Tsuji M, Yuen KY, Kwong PD, Sheng Z, Huang Y, Shapiro L & Ho DD. An antibody class with a common CDRH3 motif broadly neutralizes sarbecoviruses. Science translational medicine. 2022; 14(646):eabn6859.

21.Iketani S*, Liu L*, Guo Y*, Liu L*, Chan JF*, Huang Y, Wang M, Luo Y, Yu J, Chu H, Chik KK, Yuen TT, Yin MT, Sobieszczyk ME, Huang Y, Yuen KY, Wang HH, Sheng Z & Ho DD. Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature 2022; 604(7906):553-6.

22.Liu L, Iketani S, Guo Y, Chan JF, Wang M, Liu L, Luo Y, Chu H, Huang Y, Nair MS, Yu J, Chik KK, Yuen TT, Yoon C, To KK, Chen H, Yin MT, Sobieszczyk ME, Huang Y, Wang HH, Sheng Z, Yuen KY & Ho DD. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature 2022; 602(7898):676-81.

23.Wang Q, Li Z, Ho J, Guo Y, Yeh AY, Liu M, Wang M, Yu J, Sheng Z, Huang Y, Liu L#, Ho DD. Resistance of SARS-CoV-2 Omicron Subvariant BA.4.6 to Antibody Neutralization. The Lancet Infectious Diseases 2022 Oct 31:S1473-3099(22)00694-6.

24.Wang Q, Iketani S, Li Z, Guo Y, Yeh AY, Liu M, Yu J, Sheng Z, Huang Y, Liu L#, Ho DD. Antigenic characterization of the SARS-CoV-2 Omicron subvariant BA.2.75. Cell Host & Microbe 2022 Sep 6:S1931-3128(22)00419-X.

25.Wang Q, Guo Y, Iketani S, Nair MS, Li Z, Mohri H, Wang M, Yu J, Bowen AD, Chang JY, Shah JG, Nguyen N, Chen Z, Meyers K, Yin MT, Sobieszczyk ME, Sheng Z, Huang Y, Liu L#, Ho DD. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5. Nature 2022 Aug;608(7923):603-608.

26.Wang Q*,#, Anang S*, Iketani S, Guo Y, Liu L, Katsamba PS, Shapiro L, Ho DD, Sodroski JG#. Functional properties of the spike glycoprotein of the emerging SARS-CoV-2 variant B.1.1.529. Cell Reports 2022 Jun 14;39(11):110924.

27.Wang Q, Esnault F, Zhao M, Chiu TJ, Smith AB, Nguyen HT, Sodroski JG. Global Increases in Human Immunodeficiency Virus Neutralization Sensitivity Due to Alterations in the Membrane-Proximal External Region of the Envelope Glycoprotein Can be Minimized by Distant State 1-Stabilizing Changes. Journal of Virology 2022 Mar 15;e0187821.

28.Wang P*, Nair MS*, Liu L*, Iketani S*, Luo Y, Guo Y, Wang M, Yu J, Zhang B, Kwong PD, Graham BS, Mascola JR, Chang JY, Yin MT, Sobieszczyk M, Kyratsous CA, Shapiro L, Sheng Z, Huang Y, and Ho DD. Nature 2021; Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7. Nature 2021;593, 130-135.

29.Wang Q, Nair MS, Anang S, Zhang S, Nguyen H, Huang Y, Liu L, Ho DD, Sodroski JG. Functional differences among the spike glycoproteins of multiple emerging severe acute respiratory syndrome coronavirus 2 variants of concern. iScience 2021; Nov 19;24(11):103393.

30.Liu L, Wang P, Nair MS, Yu J, Rapp M, Wang Q, Luo Y, Chan JF, Sahi V, Figueroa A, Guo XV, Cerutti G, Bimela J, Gorman J, Zhou T, Chen Z, Yuen KY, Kwong PD, Sodroski JG, Yin MT, Sheng Z, Huang Y, Shapiro L and Ho DD. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 2020; 584(7821): 450-456.

31.Wang Q, Ma B, Liang Q, Zhu A, Wang H, Fu L, Han X, Shi X, Xiang Y, Shang H and Zhang L. Stabilized diverse HIV-1 envelope trimers for vaccine design. Emerging Microbes & Infections 2020 Dec;9(1):775-786.

32.Wang Q, Finzi A and Sodroski JG. The Conformational States of the HIV-1 Envelope Glycoproteins. Trends in Microbiology 2020 Aug;28(8):655-667.

33.Liu L, Wang P*,Nair MS*, Yu J*, Rapp M*, Wang Q*, Luo Y, Chan JF, Sahi V, Figueroa A, Guo XV, Cerutti G, Bimela J, Gorman J, Zhou T, Chen Z, Yuen KY, Kwong PD, Sodroski JG, Yin MT, Sheng Z, Huang Y, Shapiro L and Ho DD. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 2020 Aug;584(7821):450-456.

文章发表情况详见：

1.https://scholar.google.com/citations?hl=en&user=p3szl5IAAAAJ

2.https://scholar.google.com/citations?user=VLggvyoAAAAJ&hl=en

信息来源于网络，如有变更请以原发布者为准。

来源链接：

https://klv.whu.edu.cn/info/1028/9693.htm

准备申请博士后的各位老师注意了！知识人网（www.zsr.cc）每周定时更新最新的国内外博士后招聘信息以及访问学者、博士后资讯，感谢大家的关注！